3 Undervalued Healthcare Stocks Invstors Can Buy Right Now
2 extracted signals · 0 resolved · 2 still active
Parkev Tatevosian, CFAIndependent analyst profile- Source published
- 28 Sept 2026, 11:45 UTC
- Recorded by Tahlil Plus
- 28 Sept 2026, 15:17 UTC
AI-generated source summary
The healthcare industry is undergoing significant disruption, with a focus on consumers bearing more responsibility for their healthcare costs. This shift is driven by policy changes and negotiations aimed at reducing overall spending. Teladoc Health (TLADOC) presents an opportunity with an intrinsic value of $7.86 compared to its current market price of $6.13, suggesting a potential upside of approximately 28%. While its business boomed during the pandemic, growth has since plateaued, and some segments are declining. However, the company's expansion into virtual visits offers potential for future growth. Eli Lilly (LLY) is another compelling investment, with an intrinsic value of $1,493.94 against a current market price of $1,152.75. This represents a substantial upside potential, driven by its strong free cash flow growth and a robust pipeline of treatments, particularly in weight loss, which is expected to fuel continued sales increases over the next 10-20 years. Oscar Health (OSCR) is identified as one of the fastest-growing healthcare companies, with a compounded annual revenue growth rate exceeding 40% and projected revenue growth of over 20% annually. Its intrinsic value stands at $41.09, with a current market price of $30.55, indicating an upside of 34.50%. The company's strategy of leveraging AI and offering diverse healthcare services positions it well for continued success.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
2 signals remain active.
Parkev Tatevosian, CFA
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.